Retatrutide triple agonist development and comorbidity benefits
Discussed in 1 analyzed podcast episode across 1 show
Discussed On
Episodes
The Top Line · Jul 10, 2026
A $10B deal, China trial scrutiny and highlights from ADA 2026
Vertex Crinetics acquisition and rare endocrine disease expansionClinical trial regulation and China data integrity scrutinyGLP-1 agonist efficacy and weight loss outcomesOral obesity medication market competition and prescriptionsNext-generation incretin drug tolerability and dosing frequency
View Analysis